10x CEO and Cofounder Serge Saxonov reflected on how the firm's IPO got so big and how he plans to make the single-cell analysis firm even bigger.
he lawsuit, filed on the eve of 10x's IPO, alleges that 10x's new Next GEM microfluidic chips infringe a patent exclusively licensed to Bio-Rad.
In response to BD's patent suit, 10x alleged BD's single-cell products infringe its own patents. 10x also asked the judge to dismiss BD's lawsuit.
In PNAS this week: transcriptomic and epigenomic sequence differences in glioblastoma models, approach to analyze small amounts of extracellular RNA, and more.
The single-cell sequencing firm originally said it was looking to raise $100 million in its initial public offering.
Spurred to develop new microfluidic chip technology, 10x told customers not to worry about the transition but told a court there would be "guaranteed hitches."
Single-cell transcriptomic profiles for more than 1,700 malaria-causing Plasmodium berghei parasites revealed gene expression patterns that differ by parasite stage.
The single-cell analysis firm plans to use the proceeds to fund general corporate activities and potentially acquire businesses, products, or technologies.
The method allows for the annotation of cells by their genotype and capture of single-cell transcriptomes, even when the cells aren't morphologically distinct.
Using single-cell RNA-seq and other approaches, researchers looked at the four known medulloblastoma subtypes and the brain cell types from which they arise.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.